Recombinant Human Calcium-binding mitochondrial carrier protein Aralar2 (SLC25A13)

What is the basic function of SLC25A13 in cellular metabolism?

SLC25A13 encodes citrin (also known as Aralar2), which functions as the liver-type mitochondrial aspartate-glutamate carrier isoform 2 (AGC2). This protein is a critical component of the malate-aspartate shuttle (MAS), which represents the primary cellular pathway for transferring redox equivalents of NADH into mitochondria . This function is essential for maintaining oxidative glucose consumption and gluconeogenesis from lactate in liver tissues. Additionally, the MAS allows for mitochondrial synthesis and export of aspartate to the cytosol, which is crucial for protein synthesis, pyrimidine and purine production, and serves as a substrate for the urea cycle in hepatocytes .

How does SLC25A13 differ structurally and functionally from SLC25A12 (Aralar1)?

SLC25A13 (citrin/Aralar2) shares approximately 78% sequence identity with SLC25A12 (Aralar1/AGC1) . While both proteins function as aspartate-glutamate carriers with similar transport properties, they exhibit different tissue distribution patterns and subtle differences in calcium regulation mechanisms . Aralar1 is predominantly expressed in the brain and other tissues, whereas citrin is primarily expressed in the liver, kidney, and heart. The proteins have slightly different calcium regulation properties, which may contribute to their tissue-specific functions . Notably, the presence of aralar in liver Kupffer cells suggests potential therapeutic applications where aralar might substitute for citrin without triggering immune responses .

What are the known post-translational modifications of SLC25A13 that affect its function?

SLC25A13 undergoes calcium-dependent regulation through EF-hand calcium-binding domains located in its N-terminal region. These domains allow the protein to respond to changes in calcium concentrations, affecting its transport function . In experimental settings, the addition of 200 nM Ruthenium Red (RR) is used to inhibit calcium uptake into mitochondria during MAS activity assays, indicating the importance of calcium regulation for proper protein function . Research indicates that these calcium-binding domains play a critical role in modulating transport activity in response to cellular signaling events.

What are the most reliable methods for quantifying SLC25A13 protein expression in experimental samples?

Several approaches have been validated for SLC25A13 quantification:

• ELISA-based detection: Sandwich ELISA kits are available with detection ranges of 0.312-20 ng/mL and sensitivities of approximately 0.12 ng/mL for human samples. These kits demonstrate high specificity with intra-assay CV of 4.5% and inter-assay CV of 8.3% .

• Absolute quantification proteomics: This approach has been used to determine the relative levels of citrin and aralar in mouse and human liver samples. Studies have revealed significant species differences, with mouse liver having a citrin/aralar molar ratio of 7.8, while human liver is nearly devoid of aralar (CITRIN/ARALAR ratio of 397) .

• Immunoblotting: Western blot analysis using polyclonal antibodies against aralar (typically at 1/500 dilution) or monoclonal antibodies against citrin provides semi-quantitative assessment of protein levels .

• Immunofluorescence microscopy: Visualization of protein localization using antibodies against aralar (1/500 dilution) combined with mitochondrial markers such as citrate synthase (1/500 dilution) enables assessment of subcellular distribution .

How can SLC25A13 mutations be effectively identified and characterized in research settings?

Multiple complementary approaches can be employed for thorough mutation analysis:

• Direct DNA sequencing: The primary method for identifying known and novel mutations in the SLC25A13 gene .

• cDNA cloning analysis: This approach using peripheral blood lymphocytes (PBLs) has been established as a less invasive tool to identify aberrant SLC25A13 transcripts. The procedure involves PCR amplification using primer pairs that cover the entire coding region, followed by cloning and sequence analysis .

• PCR-RFLP (Restriction Fragment Length Polymorphism): Useful for screening specific known mutations in larger populations .

• In silico prediction tools: Software like PolyPhen-2 can be used to predict the functional effect of novel missense mutations, with scores above 0.85 classified as "probably damaging" and scores above 0.15 as "possibly damaging" .

• Alternative splicing variant (ASV) analysis: Identification of ASVs through cDNA cloning provides insights into pathogenic mechanisms of certain mutations .

What is the optimal experimental design for measuring malate-aspartate shuttle (MAS) activity in relation to SLC25A13 function?

The reconstitution and measurement of MAS activity requires precise experimental conditions:

• Sample preparation: Isolation of mitochondria (0.1-0.15 mg) from liver tissue using standardized protocols and resuspension in appropriate buffer (MSK buffer) .

• Reconstitution components:

  • 4 U/ml aspartate aminotransferase (GOT)

  • 6 U/ml malate dehydrogenase (MDH)

  • 66 μM NADH

  • 5 mM aspartate

  • 5 mM malate

  • 0.5 mM ADP

  • 200 nM Ruthenium Red (RR)

• Enzyme purification: To remove contaminant α-ketoglutarate from GOT, the enzyme should be dialyzed in 3 M (NH₄)₂SO₄ + 1 mM pyridoxal phosphate for 48 hours at 4°C with shaking (1:100 volume ratio) .

• Calcium calibration: Free calcium concentrations should be calibrated using fluorescent indicators such as Fura-2 and Calcium Green .

• Control considerations: Appropriate controls including mitochondria from wildtype and knockout models should be included to validate MAS activity measurements.

How do mutations in SLC25A13 lead to the spectrum of citrin deficiency disorders?

Citrin deficiency (CD) manifests as four distinct clinical phenotypes across the lifespan:

• Neonatal Intrahepatic Cholestasis caused by Citrin Deficiency (NICCD): Affects newborns and infants, presenting with jaundice, hypoproteinemia, hypoglycemia, and elevated citrulline levels .

• Silent period: Following NICCD, many patients enter a period without obvious symptoms .

• Failure to Thrive and Dyslipidemia caused by Citrin Deficiency (FTTDCD): Occurs in some post-NICCD children .

• Citrullinemia Type II (CTLN2): Adult-onset manifestation characterized by hyperammonemia, neuropsychiatric symptoms, and elevated plasma citrulline .

The pathophysiological mechanisms link to disruption of the malate-aspartate shuttle due to citrin deficiency, which leads to:

• Impaired transfer of NADH reducing equivalents into mitochondria

• Cytosolic redox imbalance (increased NADH/NAD⁺ ratio)

• Impaired aspartate export from mitochondria to cytosol

• Defects in urea cycle function, particularly affecting argininosuccinate synthetase

What evidence supports the potential of aralar (SLC25A12) as a therapeutic replacement for citrin in SLC25A13 deficiency?

Several lines of evidence support aralar's therapeutic potential:

• Functional replacement in mouse models: Studies in citrin(-/-) mice demonstrate that exogenous aralar expression reverses the increased NADH/NAD⁺ ratio observed in hepatocytes lacking citrin .

• Mitochondrial MAS activity restoration: Liver mitochondria from citrin(-/-) mice expressing liver-specific transgenic aralar show consistent increases in MAS activity (approximately 4-6 nmoles × mg protein⁻¹ × min⁻¹) compared to citrin(-/-) mice without aralar expression .

• Structural and functional similarity: Aralar shares 78% identity with citrin and has similar transport properties, suggesting functional compatibility .

• Reduced immunogenicity risk: Since aralar is expressed in many cell types, particularly in liver Kupffer cells, it is unlikely that aralar-based gene therapy would trigger an immune response .

• Species-specific considerations: Important differences exist between mouse and human liver regarding endogenous aralar levels, with human liver being virtually devoid of aralar (CITRIN/ARALAR ratio of 397 in humans vs. 7.8 in mice). This suggests that increasing aralar expression in human liver could effectively improve redox balance capacity .

How do geographic and genetic factors influence the mutation spectrum of SLC25A13?

Geographic distribution analysis of SLC25A13 mutations reveals significant patterns:

• North-South variations in China: A large NICCD cohort study of 116 Chinese cases demonstrated that four high-frequency mutations contributed a significantly larger proportion of mutated alleles in patients from south China compared to those from north China (χ² = 14.93, P<0.01), with 30°N latitude serving as the geographic dividing line .

• Mutation diversity: At least 81 different pathogenic mutations have been identified worldwide, including missense, nonsense, splice-site, deletion, and insertion variants .

• Novel mutations: Recent studies have identified 16 novel pathogenic mutations in patients from China, Japan, and Malaysia, including:

  • 9 missense mutations

  • 4 nonsense mutations

  • 1 splice-site mutation

  • 1 deletion

  • 1 large transposal insertion (IVS4ins6kb)

• Diagnosis rates: DNA diagnostic methods have shown that more than 90% of patients diagnosed with CTLN2 by enzymatic analysis carry SLC25A13 mutations in both alleles .

What experimental approaches are recommended for studying the interaction between SLC25A13 and calcium signaling pathways?

To investigate the calcium-dependent regulation of SLC25A13:

• Calcium binding assays: Use purified recombinant N-terminal domains of SLC25A13 containing the EF-hand motifs to measure calcium binding affinity using isothermal titration calorimetry or fluorescence-based assays.

• Live-cell calcium imaging: Combine fluorescent calcium indicators with tagged SLC25A13 to monitor real-time changes in transport activity in response to calcium fluctuations.

• Site-directed mutagenesis: Introduce mutations in the calcium-binding domains to assess their impact on protein function and regulation. Studies should include both loss-of-function and gain-of-function mutations.

• Reconstitution in liposomes: Incorporate purified SLC25A13 into liposomes with controlled calcium concentrations to directly measure transport activity.

• Calcium chelation effects: Use experimental designs that include calcium chelators (EGTA/BAPTA) and calcium ionophores to manipulate calcium levels while monitoring SLC25A13 activity.

How can transgenic mouse models be optimized for studying SLC25A13 function and related diseases?

Based on current research approaches, optimized transgenic models should incorporate:

• Liver-specific expression systems: Use liver-specific promoters like EAlbAAT for targeted expression, as demonstrated in the generation of liver-specific aralar transgenic mice (LAralar Tg) .

• Prevention of silencing: Include β-globin intron between the promoter and the target cDNA to decrease the possibility of silencing, as implemented in pCMV5-AlbEnh-βglobin-mAralar (pLAralar) constructs .

• Tissue-specific knockout strategies: Generate conditional knockout models using Cre-lox systems to study the tissue-specific effects of SLC25A13 deficiency.

• Humanized mouse models: Consider species differences in endogenous aralar levels when designing models. The significantly higher CITRIN/ARALAR ratio in human liver (397) compared to mouse liver (7.8) suggests that humanized models may better recapitulate human disease conditions .

• Marker incorporation: Include appropriate epitope tags (such as Flag) to facilitate detection and differentiation from endogenous proteins .

What analytical considerations are important when interpreting proteomic data related to SLC25A13 expression?

When analyzing proteomic data for SLC25A13:

• Absolute quantification approach: Use targeted proteomics with isotope-labeled internal standards to determine absolute protein quantities, as relative quantification may be misleading when comparing across tissues or species .

• Species differences: Account for the substantial variation in citrin/aralar ratios between species (7.8 in mouse liver vs. 397 in human liver), which impacts the interpretation of animal model findings .

• Tissue heterogeneity: Consider that SLC25A13 expression varies across cell types within tissues. For instance, aralar is expressed in liver Kupffer cells but not significantly in hepatocytes .

• Subcellular fractionation quality: Ensure high-quality mitochondrial isolation to accurately assess mitochondrial carrier proteins, as contamination from other cellular compartments can skew results.

• Post-translational modifications: Implement proteomic approaches that can detect relevant post-translational modifications, particularly those affecting the calcium-binding domains that regulate transport activity.

What are the most common technical challenges in SLC25A13 cDNA cloning, and how can they be addressed?

Common challenges and solutions include:

• Low expression levels: Optimize RNA extraction using specialized kits for low-abundance transcripts. Consider using peripheral blood lymphocytes (PBLs) as a less invasive source of material compared to liver biopsies .

• PCR amplification difficulties: Design nested PCR approaches with high-fidelity polymerases. For SLC25A13, effective primer combinations include:

  • First PCR: Ex-4F (5'-AACGCACGCTGCCTGGCCGTATC-3') and RACEA1 (5'-CCACCTTCACAAATTCATGCGCC-3')

  • Second PCR: RAS3 (5'-GCCGCCGGGACTAGAAGTGAGC-3') and Ex18R (5'-TGCTTCATTCCCAGGAGGGA-3')

• Clone screening efficiency: Implement "white-blue spot selection" for initial screening of positive clones, followed by PCR confirmation using appropriate primers .

• Alternative splicing detection: When analyzing cDNA clones, be vigilant for alternative splicing variants (ASVs) which may be relevant to disease mechanisms. Compare the proportion of ASVs between patients and healthy controls using statistical methods like chi-square tests .

• Reference sequence alignment: Ensure proper alignment with current reference sequences, as SLC25A13 nomenclature and reference sequences have evolved over time.

What quality control parameters should be monitored when using recombinant SLC25A13 in functional assays?

Key quality control parameters include:

• Protein purity: Verify >95% purity by SDS-PAGE and mass spectrometry before functional studies.

• Folding integrity: Assess proper folding using circular dichroism spectroscopy, focusing on secondary structure elements characteristic of mitochondrial carrier proteins.

• Mitochondrial targeting sequence status: Confirm whether the recombinant protein includes or excludes the mitochondrial targeting sequence, as this affects localization and function.

• Post-translational modifications: Verify the presence of essential modifications, particularly in calcium-binding domains.

• Functional validation: Prior to complex experiments, validate basic transport function using reconstituted liposome systems with defined substrate concentrations.

• Batch consistency: Implement lot-to-lot validation to ensure consistent protein quality across experimental timeframes.

How can researchers distinguish between primary effects of SLC25A13 deficiency and secondary metabolic adaptations in experimental models?

To differentiate primary from secondary effects:

• Time-course studies: Implement temporal analysis beginning immediately after gene deletion or inhibition to capture primary effects before compensatory mechanisms develop.

• Acute vs. chronic models: Compare acute knockdown (e.g., using siRNA) with stable genetic knockout models to distinguish immediate consequences from adapted states.

• Metabolic flux analysis: Use isotope-labeled metabolites to track changes in metabolic pathways directly linked to SLC25A13 function, particularly aspartate metabolism and the malate-aspartate shuttle.

• Tissue-specific conditional models: Employ inducible tissue-specific knockout systems to observe the immediate consequences of SLC25A13 deletion in specific cell types.

• Multi-omics integration: Combine transcriptomics, proteomics, and metabolomics data to build comprehensive models distinguishing primary pathway disruptions from secondary adaptations.

• Rescue experiments: Perform targeted rescue of specific pathways to determine which phenotypes are directly attributable to SLC25A13 deficiency.